{"product_id":"derm-vrio-analysis","title":"Journey Medical Corporation (DERM): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eCan Journey Medical Corporation (DERM) secure a lasting competitive advantage? This VRIO analysis rigorously tests its core assets against the benchmarks of Value, Rarity, Inimitability, and Organization to reveal the true source of its market strength. Dive in now to see the distilled verdict on whether its current setup is built for sustainable dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e1. Emrosi Intellectual Property \u0026amp; Patent Runway\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core protection for Journey Medical Corporation’s biggest near-term growth story, Emrosi. The intellectual property around this drug is what gives the company the time to execute its commercial strategy without an immediate generic threat. This patent runway is the moat. It’s defintely the most critical intangible asset right now.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Protecting the Growth Engine\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value here is direct: the patents protect the high-growth Emrosi asset from direct competition. In the third quarter of fiscal year 2025, Emrosi was a major contributor, generating $4.9 million in net sales. Considering the total Q3 2025 revenue hit $17.6 million, Emrosi accounted for over a quarter of the top line, and its prescriptions were ramping hard, growing 146% quarter-over-quarter to 18,198 total prescriptions. This protection is crucial as management projects Emrosi could reach peak annual net sales exceeding $200 million in the U.S. alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Long-Term Exclusivity is Uncommon\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is quite rare for a newly launched product to secure such a long period of market protection. Journey Medical Corporation states that three U.S. Orange Book listed patents are in place, extending exclusivity out to 2039. For a product launched in 2025, having protection that stretches nearly 15 years is a significant rarity in the pharmaceutical space, especially when competing against older active ingredients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Legal Barriers are High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitating this advantage is very difficult because patents are legally enforced barriers, not just easily copied business practices or processes. A competitor cannot simply reverse-engineer the formulation or marketing strategy to bypass the patent. They must wait for expiration or successfully challenge the patents in court, which is costly and uncertain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Actively Exploiting the Moat\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is clearly exploiting this asset by making it a central theme in its investor narrative. They are using the long runway to justify aggressive commercial investment, aiming for sustainable EBITDA positivity by Q4 2025. Here’s a quick look at how they are organizing around this asset:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHighlighting superiority over Oracea in investor decks.\u003c\/li\u003e\n\u003cli\u003eFocusing SG\u0026amp;A spending on Emrosi launch activities.\u003c\/li\u003e\n\u003cli\u003eSetting long-term peak sales targets based on exclusivity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the near-term pressure from payer adoption, as gross-to-net variability impacted consensus estimates in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained Advantage Confirmed\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe patent protection provides a long-term moat for their key growth driver, resulting in a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. This is the foundation upon which they plan to build market share in the estimated $200 million U.S. rosacea market.\u003c\/p\u003e\n\n\u003cp\u003eHere is the VRIO assessment summary for this critical resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (1-4)\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnables $4.9M in Q3 2025 sales and protects long-term potential.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree patents extending exclusivity to 2039 is rare for a new launch.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eInimitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLegally enforced patents are very difficult to imitate.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany is actively using the runway to drive commercial execution.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOverall Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong-term patent protection supports sustained advantage potential.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e2. Focused Dermatology Commercial Sales Force\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe focused dermatology commercial sales force is a core asset supporting the commercialization of Journey Medical Corporation's portfolio, particularly Emrosi.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe dedicated sales force directly contributes to product adoption and revenue generation, as evidenced by the company's financial performance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal net revenues for Q3 2025 reached \u003cstrong\u003e$17.6 million\u003c\/strong\u003e, a \u003cstrong\u003e21%\u003c\/strong\u003e increase compared to $14.6 million in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eEmrosi™ net sales contributed \u003cstrong\u003e$4.9 million\u003c\/strong\u003e to Q3 2025 revenue.\u003c\/li\u003e\n\u003cli\u003eEmrosi™ total prescriptions increased \u003cstrong\u003e146%\u003c\/strong\u003e over the second quarter of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eA sales force exclusively specialized and dedicated to dermatology is a less common structure compared to generalist teams in the broader pharmaceutical industry.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Force Size (Territories)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35\u003c\/strong\u003e territories\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Dermatology Sales Experience (Sales Reps)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12 yrs.\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Experience (Management\/Sales Force)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;527 yrs.\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eReplicating this specialized sales infrastructure requires significant capital outlay and time to cultivate the necessary deep-rooted customer relationships.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe sales force has deep-rooted customer relationships in their respective territories.\u003c\/li\u003e\n\u003cli\u003eThe company's senior management team has over \u003cstrong\u003e175 years\u003c\/strong\u003e collectively of sales and marketing experience at leading dermatology companies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe structure is actively deployed, focusing on key markets and maximizing product access.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCoverage in the Top 50 U.S. MSAs was reported at \u003cstrong\u003e80%\u003c\/strong\u003e in a prior presentation.\u003c\/li\u003e\n\u003cli\u003eCoverage in the U.S. Dermatology TRx Market was reported at \u003cstrong\u003e70%\u003c\/strong\u003e in a prior presentation.\u003c\/li\u003e\n\u003cli\u003eAs of July 2025, Emrosi achieved expanded payer access covering over \u003cstrong\u003e100 million\u003c\/strong\u003e commercial lives in the U.S..\u003c\/li\u003e\n\u003cli\u003eSelling, General \u0026amp; Administrative (SG\u0026amp;A) expenses for Q3 2025 were \u003cstrong\u003e$12.1 million\u003c\/strong\u003e, up from $11.4 million in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe advantage is considered temporary as competitors can eventually replicate the structure, although the established relationships provide a short-to-medium term barrier.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\/Percentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e3. Established Portfolio of Legacy Products\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable revenue base (historically accounting for about \u003cstrong\u003e90%\u003c\/strong\u003e of product sales prior to Emrosi launch) and cash flow to fund new launches. Revenues totaled \u003cstrong\u003e$17.6 million\u003c\/strong\u003e in the third quarter of 2025, representing a \u003cstrong\u003e21%\u003c\/strong\u003e increase compared to \u003cstrong\u003e$14.6 million\u003c\/strong\u003e in the third quarter of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms have legacy products, but the specific mix of \u003cstrong\u003eseven branded and three authorized generic\u003c\/strong\u003e prescription drugs is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; these are often off-patent or mature assets that competitors could acquire or already hold. Revenue for this product group in the aggregate declined \u003cstrong\u003e16%\u003c\/strong\u003e year-over-year in Q3 2025, mainly due to the impact from Accutane generic competition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team effectively manages these products alongside the Emrosi launch, contributing to a \u003cstrong\u003e67.4%\u003c\/strong\u003e gross margin in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None sustained; these are necessary but not a source of long-term outperformance.\u003c\/p\u003e\n\u003cp\u003eThe financial performance metrics for the legacy and core products, including Qbrexza, Accutane, AMZEEQ, and ZILXI, in the context of the overall company results for Q3 2025, are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Value\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Value\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe gross margin trend during 2025 demonstrates sequential improvement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Gross Margin: \u003cstrong\u003e63.5%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Gross Margin: \u003cstrong\u003e67.1%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e67.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific product groups within the legacy portfolio experienced the following year-over-year revenue change:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLegacy and core products (aggregate): Declined \u003cstrong\u003e16%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eEmrosi net sales (new product): Generated \u003cstrong\u003e$4.9 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e4. High Gross Margin Product Mix\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Directly improves profitability.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eGross margin improved sequentially in 2025 from \u003cstrong\u003e63.5%\u003c\/strong\u003e in Q1 to \u003cstrong\u003e67.1%\u003c\/strong\u003e in Q2, reaching \u003cstrong\u003e67.4%\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Q3 2025 gross margin was \u003cstrong\u003e67.4%\u003c\/strong\u003e. The Q3 2024 gross margin was \u003cstrong\u003e69.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe margin expansion is driven by net revenues from higher-margin products, specifically Emrosi and Qbrexza.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmrosi net sales in Q3 2025: \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEmrosi total prescriptions increased \u003cstrong\u003e146%\u003c\/strong\u003e over Q2 2025.\u003c\/li\u003e\n\u003cli\u003eEmrosi total prescriptions reached \u003cstrong\u003e18,198\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eUnique Emrosi prescribers surpassed \u003cstrong\u003e2,700\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003ePayer access for Emrosi expanded to over \u003cstrong\u003e100 million\u003c\/strong\u003e commercial lives by July 2025, up from \u003cstrong\u003e54 million\u003c\/strong\u003e in May 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: The company is organized to prioritize higher-margin products like Emrosi and Qbrexza in its sales mix.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eQ3 2025 total revenues were \u003cstrong\u003e$17.6 million\u003c\/strong\u003e, a \u003cstrong\u003e21%\u003c\/strong\u003e increase compared to $14.6 million in Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLong-term peak sales aspirations for Emrosi are stated as over \u003cstrong\u003e$200 million\u003c\/strong\u003e U.S. and over \u003cstrong\u003e$300 million\u003c\/strong\u003e globally.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e5. Management Team’s Commercialization Acumen\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eReduces execution risk on product launches, as seen with Emrosi's strong initial uptake post-April 2025 launch.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmrosi net sales in its first full quarter (Q2 2025) were \u003cstrong\u003e$2.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEmrosi initial revenue in Q1 2025 was \u003cstrong\u003e$2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEmrosi net sales accelerated to \u003cstrong\u003e$4.9 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eTotal unique prescribers for Emrosi reached \u003cstrong\u003eover 1,800\u003c\/strong\u003e by the end of Q2 2025.\u003c\/li\u003e\n\u003cli\u003ePayer coverage for Emrosi expanded from \u003cstrong\u003e30%\u003c\/strong\u003e of commercial lives in May 2025 to over \u003cstrong\u003e100 million\u003c\/strong\u003e commercial lives (approximately \u003cstrong\u003e65%\u003c\/strong\u003e) in July 2025.\u003c\/li\u003e\n\u003cli\u003eEmrosi total prescriptions increased by \u003cstrong\u003e146%\u003c\/strong\u003e from Q2 2025 to Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eHigh; the team has decades of experience commercializing some of dermatology's most successful brands.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eManagement Role\u003c\/th\u003e\n\u003cth\u003eYears of Experience (Minimum)\u003c\/th\u003e\n\u003cth\u003eKey Historical Achievement Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior Management Team (Collective)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e175 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExperience growing\/managing brands that generated over \u003cstrong\u003e$2B\u003c\/strong\u003e in sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO (Claude Maraoui)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExecuted \u003cstrong\u003emore than 50\u003c\/strong\u003e product launches.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO (Joseph Benesch)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSenior financial management positions at multiple pharmaceutical companies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCCO (Robert Nevin)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOversaw sales, trade, and managed care functions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP Business Development (Ernest Galvan)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e23 years\u003c\/strong\u003e in brand management and development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP R\u0026amp;D (Srinivas Sidgiddi, M.D.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLed dermatology franchise to \u003cstrong\u003e5\u003c\/strong\u003e NDA approvals at prior company.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP Operations (Andrew Zwible)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAssisted with the \u003cstrong\u003e$455MM\u003c\/strong\u003e acquisition of Graceway Pharmaceuticals LLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eVery difficult; relies on tacit knowledge, networks, and shared history within the leadership.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMajority of the management team and sales force were part of the commercial organization at Medicis.\u003c\/li\u003e\n\u003cli\u003eThe Medicis sale to Valeant Pharmaceuticals International Inc. occurred in \u003cstrong\u003e2012\u003c\/strong\u003e for approximately \u003cstrong\u003e$2.6B\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe leadership, including the CEO, is clearly driving the strategy and communicating execution success.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Claude Maraoui's tenure at Journey Medical is \u003cstrong\u003e11.25 years\u003c\/strong\u003e (appointed September 2014).\u003c\/li\u003e\n\u003cli\u003eCEO total yearly compensation was \u003cstrong\u003e$2.60M\u003c\/strong\u003e in a recent period.\u003c\/li\u003e\n\u003cli\u003eSelling, general and administrative (SG\u0026amp;A) expenses increased by \u003cstrong\u003e$1.6 million\u003c\/strong\u003e from Q2 2024 to Q2 2025 due to Emrosi launch activities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; deep, experienced human capital is hard to replicate.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e6. Clinical Differentiation and Guideline Inclusion (Emrosi)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a strong, objective reason for physicians to prescribe Emrosi over established competitors like Oracea®.\u003c\/p\u003e\n\u003cp\u003eEmrosi (minocycline hydrochloride extended-release capsules, 40 mg) demonstrated statistically superior efficacy in two Phase 3 trials (MVOR-1 and MVOR-2) compared to Oracea (doxycycline, 40 mg) and placebo on co-primary endpoints, which included Investigator's Global Assessment (IGA) treatment success and reduction in total inflammatory lesion count.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmrosi is the first and only oral treatment approved to address both erythema and inflammatory lesions associated with rosacea.\u003c\/li\u003e\n\u003cli\u003eThe recommended dosage is 40 mg orally, once daily, composed of 10 mg immediate-release and 30 mg extended-release minocycline beads.\u003c\/li\u003e\n\u003cli\u003eEmrosi represents the lowest oral dose of minocycline on the market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Efficacy Data from Pooled Phase 3 Trials (MVOR-1 and MVOR-2):\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Week 16)\u003c\/th\u003e\n\u003cth\u003eEmrosi (DFD-29)\u003c\/th\u003e\n\u003cth\u003eOracea (Doxycycline 40 mg)\u003c\/th\u003e\n\u003cth\u003ePlacebo\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGA Treatment Success Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean Inflammatory Lesion Reduction\u003c\/td\u003e\n\u003ctd\u003e19.2 lesions\u003c\/td\u003e\n\u003ctd\u003e14.8 lesions\u003c\/td\u003e\n\u003ctd\u003e11.3 lesions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe difference in IGA treatment success between Emrosi and both Oracea and placebo was statistically significant, with a p-value of \u0026lt;0.001 for both comparisons in the pooled analysis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; achieving statistically superior efficacy in a head-to-head trial against a long-standing standard of care like Oracea is a major hurdle.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn MVOR-1, 65.0% of subjects on Emrosi achieved IGA success versus 46.1% for Oracea (p-value of 0.01).\u003c\/li\u003e\n\u003cli\u003eIn MVOR-2, 60.1% of subjects on Emrosi achieved IGA success versus 31.4% for Oracea.\u003c\/li\u003e\n\u003cli\u003eEmrosi demonstrated a mean reduction of 21.3 lesions in MVOR-1 versus 15.8 lesions for Oracea.\u003c\/li\u003e\n\u003cli\u003eFor Clinician's Erythema Assessment (CEA) score reduction in MVOR-1, 31.7% on Emrosi achieved at least a 2-grade reduction versus 13.8% for placebo (p-value of 0.006).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires successful, high-quality Phase 3 trials and subsequent medical acceptance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe clinical data was published in the \u003cem\u003eJournal of the American Medical Association - Dermatology\u003c\/em\u003e.\u003c\/li\u003e\n\u003cli\u003eThe FDA approval was granted in November 2024.\u003c\/li\u003e\n\u003cli\u003eThe trials involved a total of 653 subjects across multiple centers in the US and Germany.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The commercial team uses this clinical validation in their messaging to drive prescription growth.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eJourney Medical Corporation's dermatology-focused sales force is preparing for launch, expected in early spring 2025.\u003c\/li\u003e\n\u003cli\u003eThe company aims to establish Emrosi as a 'new standard of care in the treatment of rosacea.'\u003c\/li\u003e\n\u003cli\u003eEmrosi is available by prescription at specialty pharmacy chains.\u003c\/li\u003e\n\u003cli\u003eThe market context is significant, as rosacea affects over 16 million people in the US, and the established competitor Oracea had an estimated market of $300 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; once a drug is embedded in clinical guidelines, switching costs for physicians are high.\u003c\/p\u003e\n\u003cp\u003eThe demonstrated statistical superiority over the prior standard of care, Oracea, positions Emrosi to potentially capture a significant share of the existing oral rosacea market.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e7. Efficient Sales \u0026amp; Marketing Model\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThis element assesses the company's commercial infrastructure's ability to drive revenue growth relative to the cost base.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The model facilitates significant top-line expansion while maintaining a relatively controlled increase in operating costs, leading to improved operating leverage metrics.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Value\u003c\/th\u003e\n\u003cth\u003eChange\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A as % of Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68.75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78.08%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+467%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe SG\u0026amp;A as a percentage of revenue decreased from 78.08% in Q3 2024 to \u003cstrong\u003e68.75%\u003c\/strong\u003e in Q3 2025, demonstrating operating leverage despite a \u003cstrong\u003e6%\u003c\/strong\u003e rise in absolute SG\u0026amp;A dollars to \u003cstrong\u003e$12.1 million\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The model is repeatedly described as 'efficient' in company communications, suggesting a lower cost-to-serve compared to industry peers, although specific comparative metrics are not publicly detailed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The underlying structure and processes supporting the commercial execution can be analyzed and replicated, but the accumulated, learned efficiencies and established payer access networks require significant time and investment to match.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is explicitly structured around this lean, focused commercial approach, evidenced by strategic product prioritization aimed at maximizing operating leverage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe growth is heavily concentrated in the newer product, Emrosi™, which generated \u003cstrong\u003e$4.9 million\u003c\/strong\u003e in net sales in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eGross margin has shown sequential improvement throughout 2025: Q1 at \u003cstrong\u003e63.5%\u003c\/strong\u003e, Q2 at \u003cstrong\u003e67.1%\u003c\/strong\u003e, and Q3 at \u003cstrong\u003e67.4%\u003c\/strong\u003e, driven by higher-margin products like Emrosi and Qbrexza.\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A for Q3 2025 included non-cash stock compensation expense of \u003cstrong\u003e$1.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While currently providing an advantage through superior cost control relative to revenue growth, efficiency gains are susceptible to erosion as the company scales its sales force or if market conditions necessitate increased promotional spending.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e8. Strategic Acquisition and Licensing Focus\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProvides a clear, external pathway to replenish the pipeline and acquire differentiated assets beyond internal R\u0026amp;D. The license agreement with Maruho resulted in $19.0 million of revenue in 2023.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; many firms do this, but Journey Medical's specific focus on 'undervalued assets' in dermatology is a defined niche. The company markets eight branded and three authorized generic prescription drugs.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eEasy; competitors can adopt the same strategy, though finding the right deals is the hard part.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company explicitly welcomes opportunities for licensing and acquisitions to improve patient lives. The company entered into a $20.0 million credit facility in December 2023.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone sustained; it's a standard strategic lever, not a unique resource.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction\/Event\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eFinancial Impact\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaruho License Agreement (Upfront Fee)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003ctd\u003e$19.0 million in revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaruho License Agreement (Royalties)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003ctd\u003e$0.5 million in product-related royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSWK Holdings Credit Facility\u003c\/td\u003e\n\u003ctd\u003eDecember 2023\u003c\/td\u003e\n\u003ctd\u003e$20.0 million facility entered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCutia Therapeutics Milestone Payment (Amzeeq® China Approval)\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$1.0 million milestone payment received\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDFD-29 Agreement Consideration (Stock Issuance at IPO)\u003c\/td\u003e\n\u003ctd\u003eNovember 2021\u003c\/td\u003e\n\u003ctd\u003e545,131 unregistered shares issued to DRL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eAcquisition of Qbrexza from Dermira, Inc. in May 2021.\u003c\/li\u003e\n\u003cli\u003eThe company's portfolio includes eight branded and three authorized generic prescription drugs.\u003c\/li\u003e\n\u003cli\u003eThe $19.0 million upfront payment from Maruho represented a substantial portion of Other Revenue in Q3 2023, which rose from $73,000 in Q3 2022 to $19.3 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eJourney Medical Corporation (DERM) - VRIO Analysis: \u003cstrong\u003e9. Solid Liquidity Position (as of 9\/30\/2025)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides operational flexibility and reduces immediate financing risk; cash and equivalents stood at \u003cstrong\u003e$24.9 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; while not massive, achieving positive Adjusted EBITDA of \u003cstrong\u003e$1.7 million\u003c\/strong\u003e in Q3 2025 strengthens this position.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy; cash balances are public information and can be replicated through financing or operations.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe finance function is managing burn effectively, moving toward the stated goal of EBITDA positivity by year-end 2025. EBITDA for Q3 2025 was a negative \u003cstrong\u003e$0.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this is a financial state, not an enduring capability, and can change quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Liquidity and Profitability Metrics (as of 9\/30\/2025)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 9\/30\/2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 12\/31\/2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003eNegative \u003cstrong\u003e$0.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSupporting Financial Data for Q3 2025\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSG\u0026amp;A expenses totaled \u003cstrong\u003e$12.1 million\u003c\/strong\u003e for the third quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eNoncash stock compensation expense included in SG\u0026amp;A was \u003cstrong\u003e$1.9 million\u003c\/strong\u003e for the three-month period ended September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eGross margin was \u003cstrong\u003e67.4%\u003c\/strong\u003e in the third quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eGross margin improved sequentially from \u003cstrong\u003e63.5%\u003c\/strong\u003e in Q1 2025 and \u003cstrong\u003e67.1%\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eTotal revenues of \u003cstrong\u003e$17.6 million\u003c\/strong\u003e represented a \u003cstrong\u003e21%\u003c\/strong\u003e increase compared to $14.9 million in the third quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516150243477,"sku":"derm-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/derm-vrio-analysis.png?v=1740187450","url":"https:\/\/dcf-model.com\/fr\/products\/derm-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}